Medtide Inc. (HKG:3880) took in HK$428.8 million in net proceeds from its initial public offering in Hong Kong after pricing the shares at the top end of the indicative price range.
The peptide-focused CRDMO priced the IPO shares at HK$30.60 apiece, the upper limit of the price guidance of as low as HK$28.40, according to a Friday after-market hours filing.
The Hong Kong public offer portion of the deal was 301.15 times subscribed, triggering the reallocation of 6,720,000 shares from the international offering and taking the total number of shares offered under this tranche to 8,400,000 from 1,680,000 initially.
The international offering was 2.43 times subscribed and the company issued 8,400,000 shares, reduced from 15,120,000 shares initially following the reallocation.
Medtide will make its trading debut on the Hong Kong bourse Monday, June 30.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。